Bruker has announced the planned discontinuation of the IsoSpark and IsoLight platforms. Customers with questions about transition options and last-time-buy opportunities should contact their Bruker sales representative.
In this Webinar we discuss:
CAR T cells as an adoptive cell therapy to treat cancer
Trivalent CAR T cells to treat relapsed and refractory B cell leukemia
Modulation of T cell molecules to enhance CAR T cell functionality